ストックスクリーナーアプリを入手
0.94
4.44%
0.04
前日終値:
$0.90
開ける：
$0.9067
24時間の取引高:
14,551
Relative Volume:
0.23
時価総額：
$9.78M
収益：
$1.52M
当期純損益:
$-70.60M
株価収益率:
-1.119
EPS:
-0.84
ネットキャッシュフロー:
$-57.34M
1週間 パフォーマンス:
-8.74%
1か月 パフォーマンス:
-12.15%
6か月 パフォーマンス:
-45.66%
1年 パフォーマンス:
+251.01%
1日の値動き範囲:
$0.9005
$0.9705
1週間の範囲:
$0.8801
$1.085
52週間の値動き範囲:
$0.20
$4.44
Pavmed Inc Stock (PAVM) Company Profile
PAVM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.94 | 9.78M | 1.52M | -70.60M | -57.34M | -0.84 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-05 | 開始されました | Ascendiant Capital Markets | Buy |
| 2018-06-28 | 開始されました | Maxim Group | Buy |
Pavmed Inc (PAVM) 最新ニュース
Symbol Lookup - GuruFocus.com
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Vi - GuruFocus.com
PAVmed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Diagnostics Provides Business Update and Third Quarter 202 - GuruFocus.com
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - PR Newswire
PAVmed Q3 2024 Earnings Preview - MSN
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, D - GuruFocus.com
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - PR Newswire
PAVmed Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Earnings call: PAVmed reports strategic shifts and Q3 financials - Investing.com
PAVmed Inc. (NASDAQ:PAVM) Q3 2024 Earnings Call Transcript - Insider Monkey
PAVmed Inc. (PAVM) Quarterly 10-Q Report - Quartzy
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring - Yahoo Finance
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Reven - GuruFocus.com
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring By GuruFocus - Investing.com Canada
First Manhattan Co. LLC's Strategic Acquisition of PAVmed Inc Sh - GuruFocus.com
PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com
PAVmed Reports Record Revenue and Strategic Restructuring - TipRanks
PAVmed Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics' EsoGuard Revenue Surges 50% YoY, Sets Record Testing Volume in Q3 | PAVM Stock News - StockTitan
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results – Company Announcement - Financial Times
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication – Company AnnouncementFT.com - Financial Times
Finansavisen - Finansavisen
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers - BioSpace
Lucid Diagnostics expands direct contracting for cancer testing - Investing.com
Lucid Diagnostics expands direct contracting for cancer testing By Investing.com - Investing.com Canada
Lucid Diagnostics Expands Direct Contracting Initiative with Mul - GuruFocus.com
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 - GuruFocus.com
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - Kilgore News Herald
Lucid Diagnostics to Participate in Upcoming Investor Conferences - GuruFocus.com
Lucid Diagnostics gets notice of allowance for patent underlying its esoguard esophageal DNA test - MSN
Veris Health receives $1.8M NIH grant for cancer care - Mobihealth News
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - BioSpace
Lucid Diagnostics secures US patent for esophageal cancer test - Investing.com
Lucid Diagnostics stock maintains Buy rating from BTIG - Investing.com India
Lucid Diagnostics stock maintains Buy rating from BTIG By Investing.com - Investing.com South Africa
PAVmed, Veris Health get USD 1.8M NIH grant - Medical Buyer
PAVmed subsidiary receives $1.8 million NIH grant for cancer care By Investing.com - Investing.com South Africa
PAVmed subsidiary receives $1.8 million NIH grant for cancer care - Investing.com India
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care - PR Newswire
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - PR Newswire
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 - StreetInsider.com
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 – Company Announcement - Financial Times
Contrasting enVVeno Medical (NASDAQ:NVNO) and Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players - Financial Times
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer T - GuruFocus.com
Lucid Diagnostics Announces Multiple Presentations at the Upcomi - GuruFocus.com
Lucid Diagnostics Strengthens and Expands Market Access and Dire - GuruFocus.com
Pavmed Inc (PAVM) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
大文字化:
|
ボリューム (24 時間):